董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Oded S. Lieberman | -- | Chief Executive Officer and Director | 58 | 211.90万美元 | 未持股 | 2017-03-29 |
| Robert Taub | 男 | Chairman of the Board | 69 | 未披露 | 未持股 | 2017-03-29 |
| Uwe Wascher | 男 | Director | 75 | 未披露 | 未持股 | 2017-03-29 |
| Alla Felder | 女 | Director | 43 | 未披露 | 未持股 | 2017-03-29 |
| Jonathan Kalman | 男 | Director | 59 | 未披露 | 未持股 | 2017-03-29 |
| Larry Ellberger | 男 | Director | 69 | 未披露 | 未持股 | 2017-03-29 |
| Shmuel Cabilly | 男 | Director | 75 | 未披露 | 未持股 | 2017-03-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Oded S. Lieberman | -- | Chief Executive Officer and Director | 58 | 211.90万美元 | 未持股 | 2017-03-29 |
| Sheila Oren | 女 | Chief Medical Officer | 55 | 58.84万美元 | 未持股 | 2017-03-29 |
| Oron Yacoby Zeevi | 女 | Chief Scientific Officer | 56 | 46.69万美元 | 未持股 | 2017-03-29 |
| Roy Golan | 男 | Chief Financial Officer | 43 | 80.13万美元 | 未持股 | 2017-03-29 |
| Sharon Cohen Vered | 女 | Vice President, Chemistry, Manufacturing and Controls | 50 | 33.52万美元 | 未持股 | 2017-03-29 |
| Revital Mandil Levin | 女 | Vice President, Corporate Development | 42 | 未披露 | 未持股 | 2017-03-29 |
| Eran Shor | 男 | Vice President, Devices | 47 | 未披露 | 未持股 | 2017-03-29 |
| Tami Yardeni | 女 | Chief Operating Officer | 45 | 未披露 | 未持股 | 2017-03-29 |
| Ziva Mesika | 女 | Vice President, Regulatory Affairs | 53 | 未披露 | 未持股 | 2017-03-29 |
董事简历
中英对照 | 中文 | 英文- Oded S. Lieberman
-
Oded S. Lieberman，2007年12月以来，他一直是我们的首席执行官。从2005年到2013年，他担任我们董事会的主席。从2000年到2004年，他担任Proteologics, Inc.的首席执行官和总裁。1995年Omrix Biopharmaceuticals, Ltd.或Omrix成立以来直到1999年，他担任外科产品副总裁。他还担任过一些卫生保健公司的董事会成员。1984年他以优等成绩获得了the Hebrew University of Jerusalem 的生物学学士学位，Hebrew University of Jerusalem的生物学博士学位和欧洲工商管理学院（ INSEAD，枫丹白露）的工商管理硕士学位。
Oded S. Lieberman has served as our Chief Executive Officer since December 2007 and as the Chairman of our board of directors from 2005 to 2013. From 2000 to 2004 Dr. Lieberman served as Chief Executive Officer and President of Proteologics, Inc. Dr. Lieberman served as Vice President of Surgical Products with Omrix Biopharmaceuticals, Ltd., or Omrix, since its founding in 1995 until 1999. Dr. Lieberman has also served as a member of the boards of several health care companies. Dr. Lieberman received a BSc in Biology cum laude in 1984 from the Hebrew University of Jerusalem and holds both a PhD in Biology from the Hebrew University of Jerusalem and an MBA from INSEAD (Fontainebleau). - Oded S. Lieberman，2007年12月以来，他一直是我们的首席执行官。从2005年到2013年，他担任我们董事会的主席。从2000年到2004年，他担任Proteologics, Inc.的首席执行官和总裁。1995年Omrix Biopharmaceuticals, Ltd.或Omrix成立以来直到1999年，他担任外科产品副总裁。他还担任过一些卫生保健公司的董事会成员。1984年他以优等成绩获得了the Hebrew University of Jerusalem 的生物学学士学位，Hebrew University of Jerusalem的生物学博士学位和欧洲工商管理学院（ INSEAD，枫丹白露）的工商管理硕士学位。
- Oded S. Lieberman has served as our Chief Executive Officer since December 2007 and as the Chairman of our board of directors from 2005 to 2013. From 2000 to 2004 Dr. Lieberman served as Chief Executive Officer and President of Proteologics, Inc. Dr. Lieberman served as Vice President of Surgical Products with Omrix Biopharmaceuticals, Ltd., or Omrix, since its founding in 1995 until 1999. Dr. Lieberman has also served as a member of the boards of several health care companies. Dr. Lieberman received a BSc in Biology cum laude in 1984 from the Hebrew University of Jerusalem and holds both a PhD in Biology from the Hebrew University of Jerusalem and an MBA from INSEAD (Fontainebleau).
- Robert Taub
-
Robert Taub，自2007年7月以来，他一直是我们的董事会的成员。2013年11月以来，他担任主席。从1995年6月到1995年12月，他创建并担任Omrix（生物制药公司，为生物外科手术和免疫治疗市场开发、生产和销售生物制品，2008年被强生（Johnson & Johnson）收购，随后在纳斯达克（NASDAQ）上市）总裁，首席执行官和董事会成员。2009年担任Nyxoah S.A.（他一手创立的公司，开发植入治疗睡眠呼吸暂停）的主席和LifeBond（开发外科密封剂的公司）的董事。他持有RUCA Antwerp University的语言学士学位和INSEAD France的工商管理硕士学位。
Robert Taub has served as a member of our board of directors since July 2007 and as its Chairman since November 2013. From June 1995 to December 2008 Mr. Taub founded and served as President, Chief Executive Officer and a member of the board of directors of Omrix, a biopharmaceutical company that developed, manufactured and marketed biological products for the biosurgical and immunotherapy markets and which was acquired by Johnson & Johnson in 2008 following a listing on NASDAQ. In 2009 Mr. Taub served as Chairman of Nyxoah S.A., a company that he co-founded, which develops implants to treat sleep apnea, and a director of LifeBond, Ltd., a company that develops surgical sealants. Mr. Taub holds a BA in Languages from RUCA Antwerp University and an MBA from INSEAD France. - Robert Taub，自2007年7月以来，他一直是我们的董事会的成员。2013年11月以来，他担任主席。从1995年6月到1995年12月，他创建并担任Omrix（生物制药公司，为生物外科手术和免疫治疗市场开发、生产和销售生物制品，2008年被强生（Johnson & Johnson）收购，随后在纳斯达克（NASDAQ）上市）总裁，首席执行官和董事会成员。2009年担任Nyxoah S.A.（他一手创立的公司，开发植入治疗睡眠呼吸暂停）的主席和LifeBond（开发外科密封剂的公司）的董事。他持有RUCA Antwerp University的语言学士学位和INSEAD France的工商管理硕士学位。
- Robert Taub has served as a member of our board of directors since July 2007 and as its Chairman since November 2013. From June 1995 to December 2008 Mr. Taub founded and served as President, Chief Executive Officer and a member of the board of directors of Omrix, a biopharmaceutical company that developed, manufactured and marketed biological products for the biosurgical and immunotherapy markets and which was acquired by Johnson & Johnson in 2008 following a listing on NASDAQ. In 2009 Mr. Taub served as Chairman of Nyxoah S.A., a company that he co-founded, which develops implants to treat sleep apnea, and a director of LifeBond, Ltd., a company that develops surgical sealants. Mr. Taub holds a BA in Languages from RUCA Antwerp University and an MBA from INSEAD France.
- Uwe Wascher
-
Uwe Wascher，2007年7月以来，他曾担任我们的董事会成员。2000年他创立 Wascher and Partner，该公司专门从事并购咨询和特种化学品和塑料领域创业的咨询。从1984年到2000年，他担任General Electric Compan的副总裁。目前，他担任 Polymer Logistics N.V., Polyscope Polymers B.V。 和Nyxoah S.A.的非执行董事。他持有Massachusetts Institute of Technology的高分子科学硕士学位。
Uwe Wascher has served as a member of our board of directors since July 2007. In 2000 Mr. Wascher founded Wascher and Partner, a company that specializes in mergers and acquisitions consultancy and start-up advice in the specialty chemicals and plastics fields. From 1984 to 2000 Mr. Wascher served as a vice president of General Electric Company. Currently, Mr. Wascher serves as a non-executive director of Polymer Logistics N.V., Polyscope Polymers B.V. and Nyxoah S.A. Mr. Wascher holds a MSc in polymer science from the Massachusetts Institute of Technology. - Uwe Wascher，2007年7月以来，他曾担任我们的董事会成员。2000年他创立 Wascher and Partner，该公司专门从事并购咨询和特种化学品和塑料领域创业的咨询。从1984年到2000年，他担任General Electric Compan的副总裁。目前，他担任 Polymer Logistics N.V., Polyscope Polymers B.V。 和Nyxoah S.A.的非执行董事。他持有Massachusetts Institute of Technology的高分子科学硕士学位。
- Uwe Wascher has served as a member of our board of directors since July 2007. In 2000 Mr. Wascher founded Wascher and Partner, a company that specializes in mergers and acquisitions consultancy and start-up advice in the specialty chemicals and plastics fields. From 1984 to 2000 Mr. Wascher served as a vice president of General Electric Company. Currently, Mr. Wascher serves as a non-executive director of Polymer Logistics N.V., Polyscope Polymers B.V. and Nyxoah S.A. Mr. Wascher holds a MSc in polymer science from the Massachusetts Institute of Technology.
- Alla Felder
-
Alla Felder已经同意加入我们的董事会，于我们的普通股在纳斯达克（NASDAQ）上市之日生效。根据以色列公司法律（Israeli Companies Law），公司打算让她担任外部董事，须在我们的股东会议上批准，这将在本次发行完成的三个月之内举行。她于2014年10月被任命为担任Carmit Candy Industries Ltd.（在TASE上市的公司）的董事。此外，自2010年以来她担任两个科技公司的外部首席财务官，同时也服务于以下纳斯达克（NASDAQ）和/或TASE上市的公司的董事会：Enlight Renewable Energy Ltd. Eurocom group； Crow Technologies 1977 Ltd.； Argaman Industries Ltd.； Zmiha Ltd.和Profit Industries Ltd.。在同时期她也服务于一些私营企业的董事会。自2003年以来她在以色列里雄莱锡安的管理学院学术研究部门（College of Management Academic Studies Division）进行各种会计课程演讲。从1997年到2010年她在PriceWaterhouseCoopers工作，在那里她获得高级经理的职位，带领审计小组（审计几家公司的不同部门）。她获得以色列里雄莱锡安的管理学院学术研究部门（College of Management Academic Studies Division）的工商管理和会计学位，纽约城市大学（City University of New York）的金融科学行政硕士学位。
Alla Felder has served as a director on our board of directors and a chairperson of our audit committee and a member of our compensation committee since May 6 2019. Ms. Felder currently serves as a Director in numerous publicly listed leading Israeli companies across several industries, such as Enlight Renewable Energy Ltd., Ashtrom Properties Ltd., Carmit Industries Ltd. and Argaman Industries Ltd. Ms. Felder also served on the board of Neuroderm Ltd., leading up to its acquisition by Mitsubishi Tanabe Pharma Corporation in 2017. Ms. Felder is a business and financial advisor and currently serves as an external CFO for several technology companies and is also a lecturer in the College of Management Academic Studies Division. From 1997 to 2010 Ms. Felder was with PriceWaterhouseCoopers where she served in her last role as a Senior Manager. - Alla Felder已经同意加入我们的董事会，于我们的普通股在纳斯达克（NASDAQ）上市之日生效。根据以色列公司法律（Israeli Companies Law），公司打算让她担任外部董事，须在我们的股东会议上批准，这将在本次发行完成的三个月之内举行。她于2014年10月被任命为担任Carmit Candy Industries Ltd.（在TASE上市的公司）的董事。此外，自2010年以来她担任两个科技公司的外部首席财务官，同时也服务于以下纳斯达克（NASDAQ）和/或TASE上市的公司的董事会：Enlight Renewable Energy Ltd. Eurocom group； Crow Technologies 1977 Ltd.； Argaman Industries Ltd.； Zmiha Ltd.和Profit Industries Ltd.。在同时期她也服务于一些私营企业的董事会。自2003年以来她在以色列里雄莱锡安的管理学院学术研究部门（College of Management Academic Studies Division）进行各种会计课程演讲。从1997年到2010年她在PriceWaterhouseCoopers工作，在那里她获得高级经理的职位，带领审计小组（审计几家公司的不同部门）。她获得以色列里雄莱锡安的管理学院学术研究部门（College of Management Academic Studies Division）的工商管理和会计学位，纽约城市大学（City University of New York）的金融科学行政硕士学位。
- Alla Felder has served as a director on our board of directors and a chairperson of our audit committee and a member of our compensation committee since May 6 2019. Ms. Felder currently serves as a Director in numerous publicly listed leading Israeli companies across several industries, such as Enlight Renewable Energy Ltd., Ashtrom Properties Ltd., Carmit Industries Ltd. and Argaman Industries Ltd. Ms. Felder also served on the board of Neuroderm Ltd., leading up to its acquisition by Mitsubishi Tanabe Pharma Corporation in 2017. Ms. Felder is a business and financial advisor and currently serves as an external CFO for several technology companies and is also a lecturer in the College of Management Academic Studies Division. From 1997 to 2010 Ms. Felder was with PriceWaterhouseCoopers where she served in her last role as a Senior Manager.
- Jonathan Kalman
-
Jonathan Kalman已经同意加入我们的董事会，于我们的普通股在纳斯达克（NASDAQ）上市之日生效。根据以色列公司法律（Israeli Companies Law），公司打算让他担任外部董事，须在我们的股东会议上批准，这将在本次发行完成的三个月之内举行。自2005年以来他担任Dion Investments Ltd.（私人投资公司，由他成立于1999年）的首席执行官。他目前担任Dion Investments Ltd., Dion Sharon Ltd., Belmont Ltd., Success Bug Ltd., Success Bug Israel Ltd., LeadRush Ltd.和Evolution Media + Ltd.的董事。他目前也服务于The Jerusalem Print Workshop（非盈利艺术中心，致力于以色列平面艺术的进步）的董事会。
Jonathan Kalman has served as a member of our board of directors until January 2017 as an external director since November 2014. Since 2005 he has served as the Chief Executive Officer of Dion Investments Ltd., a privately held investment company, which Mr. Kalman founded in 1999. Mr. Kalman also currently serves as a director for Dion Investments Ltd., Dion Sharon Ltd., Belmont Ltd., Success Bug Ltd., Success Bug Israel Ltd., LeadRush Ltd. and E.Real Success Ltd. He is also currently on the board of The Jerusalem Print Workshop, a non-profit art center dedicated to the advancement of the graphic arts in Israel. - Jonathan Kalman已经同意加入我们的董事会，于我们的普通股在纳斯达克（NASDAQ）上市之日生效。根据以色列公司法律（Israeli Companies Law），公司打算让他担任外部董事，须在我们的股东会议上批准，这将在本次发行完成的三个月之内举行。自2005年以来他担任Dion Investments Ltd.（私人投资公司，由他成立于1999年）的首席执行官。他目前担任Dion Investments Ltd., Dion Sharon Ltd., Belmont Ltd., Success Bug Ltd., Success Bug Israel Ltd., LeadRush Ltd.和Evolution Media + Ltd.的董事。他目前也服务于The Jerusalem Print Workshop（非盈利艺术中心，致力于以色列平面艺术的进步）的董事会。
- Jonathan Kalman has served as a member of our board of directors until January 2017 as an external director since November 2014. Since 2005 he has served as the Chief Executive Officer of Dion Investments Ltd., a privately held investment company, which Mr. Kalman founded in 1999. Mr. Kalman also currently serves as a director for Dion Investments Ltd., Dion Sharon Ltd., Belmont Ltd., Success Bug Ltd., Success Bug Israel Ltd., LeadRush Ltd. and E.Real Success Ltd. He is also currently on the board of The Jerusalem Print Workshop, a non-profit art center dedicated to the advancement of the graphic arts in Israel.
- Larry Ellberger
-
Larry Ellberger， 2009年9月，他被任命为公司的董事会主席，并自2003年8月起，一直是Celldex的董事。2003年至2012年7月，他是HVA公司的创办合伙人，一家咨询公司，专门从事制药、生物技术、药物输送和医疗设备公司的业务开发、产品收购和许可以及兼并和收购。2005年10月至2006年5月，他是PDI公司的临时首席执行官，一家向生物制药行业提供销售及市场推广服务的提供商。此前，他是PDI的董事局成员和审计委员会主席。2000年至2003年，他担任Powderject 公司的高级副总裁，一家英国疫苗公司。他也是Powderject的董事会成员。1995年至1999年，他曾在格雷斯公司担任多个职位，包括担任临时首席执行官、首席财务官兼战略规划和发展的高级副总裁。1975年至1995年，他在美国氰胺公司担任多个高级管理职位，在过去4年担任公司发展的副总裁。他目前就职于犹太儿童博物馆以及NeuroDerm有限公司的董事会，是一家私人持有的以色列生物技术公司。2008年被强生公司收购之前，他曾任Omrix生物制药公司的董事会主席。
Larry Ellberger was appointed Chairman of the Board of Directors in September 2009 and has been a director of Celldex since August 2003. Mr. Ellberger was formerly Chairman of the Board of Omrix BioPharmaceuticals, Inc. until its acquisition by Johnson & Johnson in 2008. From 2003 to July 2012 Mr. Ellberger was Founding Partner of HVA, Inc., a consulting firm specializing in business development, product acquisition and licensing, and mergers and acquisitions for pharmaceutical, biotechnology, drug delivery and medical device companies. From October 2005 to May 2006Mr. Ellberger was Interim Chief Executive Officer of PDI, Inc., a provider of sales and marketing services to the biopharmaceutical industry. Previously, he was a member of the Board of Directors of PDI and Chairman of the Audit Committee. From 2000 to 2003 Mr. Ellberger was Senior Vice President and a member of the Board of Directors of Powderject PLC, a U.K. vaccine company. From 1995 to 1999 Mr. Ellberger held several senior executive positions at W.R. Grace & Co. including Interim Chief Executive Officer, Chief Financial Officer and Senior Vice President, Strategic Planning and Development. From 1975 to 1995 Mr. Ellberger held numerous senior executive positions at American Cyanamid Company, serving the last four years as Vice President, Corporate Development. Mr. Ellberger currently serves on the Board of Directors and is a member of the Audit and Nominating Committees of NeuroDerm, Ltd., a NASDAQ-listed Israeli biotech company. He is also a Director of The Jewish Children's Museum. Mr. Ellberger received a B.A. in Economics from Columbia College and a B.Sc. in Chemical Engineering from Columbia School of Engineering. - Larry Ellberger， 2009年9月，他被任命为公司的董事会主席，并自2003年8月起，一直是Celldex的董事。2003年至2012年7月，他是HVA公司的创办合伙人，一家咨询公司，专门从事制药、生物技术、药物输送和医疗设备公司的业务开发、产品收购和许可以及兼并和收购。2005年10月至2006年5月，他是PDI公司的临时首席执行官，一家向生物制药行业提供销售及市场推广服务的提供商。此前，他是PDI的董事局成员和审计委员会主席。2000年至2003年，他担任Powderject 公司的高级副总裁，一家英国疫苗公司。他也是Powderject的董事会成员。1995年至1999年，他曾在格雷斯公司担任多个职位，包括担任临时首席执行官、首席财务官兼战略规划和发展的高级副总裁。1975年至1995年，他在美国氰胺公司担任多个高级管理职位，在过去4年担任公司发展的副总裁。他目前就职于犹太儿童博物馆以及NeuroDerm有限公司的董事会，是一家私人持有的以色列生物技术公司。2008年被强生公司收购之前，他曾任Omrix生物制药公司的董事会主席。
- Larry Ellberger was appointed Chairman of the Board of Directors in September 2009 and has been a director of Celldex since August 2003. Mr. Ellberger was formerly Chairman of the Board of Omrix BioPharmaceuticals, Inc. until its acquisition by Johnson & Johnson in 2008. From 2003 to July 2012 Mr. Ellberger was Founding Partner of HVA, Inc., a consulting firm specializing in business development, product acquisition and licensing, and mergers and acquisitions for pharmaceutical, biotechnology, drug delivery and medical device companies. From October 2005 to May 2006Mr. Ellberger was Interim Chief Executive Officer of PDI, Inc., a provider of sales and marketing services to the biopharmaceutical industry. Previously, he was a member of the Board of Directors of PDI and Chairman of the Audit Committee. From 2000 to 2003 Mr. Ellberger was Senior Vice President and a member of the Board of Directors of Powderject PLC, a U.K. vaccine company. From 1995 to 1999 Mr. Ellberger held several senior executive positions at W.R. Grace & Co. including Interim Chief Executive Officer, Chief Financial Officer and Senior Vice President, Strategic Planning and Development. From 1975 to 1995 Mr. Ellberger held numerous senior executive positions at American Cyanamid Company, serving the last four years as Vice President, Corporate Development. Mr. Ellberger currently serves on the Board of Directors and is a member of the Audit and Nominating Committees of NeuroDerm, Ltd., a NASDAQ-listed Israeli biotech company. He is also a Director of The Jewish Children's Museum. Mr. Ellberger received a B.A. in Economics from Columbia College and a B.Sc. in Chemical Engineering from Columbia School of Engineering.
- Shmuel Cabilly
-
Shmuel Cabilly，他一直担任我们董事会的成员（2008年12月以来）。他是免疫学领域的科学家和发明家。他的重大突破发明相关重组抗体生产。他也曾担任Ethrog Biotechnology公司的联合创始人兼首席科学家，发明了干缓冲技术使生产的一次性装置包含没有液体，以及小区域内凝胶电泳以及分子分离技术。2001年Ethrog公司被Invitrogen公司（目前是Thermo Fisher公司）收购。他是一些以色列私人和上市的高科技公司的董事会成员，包括RedHill公司、Biopharma公司、BioCep, Pango公司、Oplon公司、Efranat公司、ViDAC公司。
Shmuel Cabilly has served as a member of our board of directors since September 2009. Dr. Cabilly is a scientist and inventor in the field of immunology. Dr. Cabilly was the named inventor of the two key patents relating to artificial synthesis of antibody molecules, commonly referred to as the “Cabilly patents.” Dr. Cabilly was also the co-founder and served as the Chief Scientist of Ethrog Biotechnologies Ltd., where he invented dry buffer technologies enabling the production of a disposable apparatus for gel electrophoresis containing no liquid, as well as a technology for molecular separation within small zones. In 2001 Ethrog Biotechnologies Ltd. was purchased by Invitrogen Corp. Thermo Fisher Scientific Inc.. Dr. Cabilly serves as a director in several high-tech companies, among them are RedHill Biopharma Ltd., Ornim Medical Ltd., Pango Mobile Parking Ltd., Oplon Pure Science Ltd., Efranat Ltd. and ViDAC Pharma Ltd. Dr. Cabilly holds a BSc in Biology from the Ben Gurion University of Be’er Sheva, and an MSc and a PhD in Immunology and Microbiology from the Hebrew University of Jerusalem. - Shmuel Cabilly，他一直担任我们董事会的成员（2008年12月以来）。他是免疫学领域的科学家和发明家。他的重大突破发明相关重组抗体生产。他也曾担任Ethrog Biotechnology公司的联合创始人兼首席科学家，发明了干缓冲技术使生产的一次性装置包含没有液体，以及小区域内凝胶电泳以及分子分离技术。2001年Ethrog公司被Invitrogen公司（目前是Thermo Fisher公司）收购。他是一些以色列私人和上市的高科技公司的董事会成员，包括RedHill公司、Biopharma公司、BioCep, Pango公司、Oplon公司、Efranat公司、ViDAC公司。
- Shmuel Cabilly has served as a member of our board of directors since September 2009. Dr. Cabilly is a scientist and inventor in the field of immunology. Dr. Cabilly was the named inventor of the two key patents relating to artificial synthesis of antibody molecules, commonly referred to as the “Cabilly patents.” Dr. Cabilly was also the co-founder and served as the Chief Scientist of Ethrog Biotechnologies Ltd., where he invented dry buffer technologies enabling the production of a disposable apparatus for gel electrophoresis containing no liquid, as well as a technology for molecular separation within small zones. In 2001 Ethrog Biotechnologies Ltd. was purchased by Invitrogen Corp. Thermo Fisher Scientific Inc.. Dr. Cabilly serves as a director in several high-tech companies, among them are RedHill Biopharma Ltd., Ornim Medical Ltd., Pango Mobile Parking Ltd., Oplon Pure Science Ltd., Efranat Ltd. and ViDAC Pharma Ltd. Dr. Cabilly holds a BSc in Biology from the Ben Gurion University of Be’er Sheva, and an MSc and a PhD in Immunology and Microbiology from the Hebrew University of Jerusalem.
高管简历
中英对照 | 中文 | 英文- Oded S. Lieberman
Oded S. Lieberman，2007年12月以来，他一直是我们的首席执行官。从2005年到2013年，他担任我们董事会的主席。从2000年到2004年，他担任Proteologics, Inc.的首席执行官和总裁。1995年Omrix Biopharmaceuticals, Ltd.或Omrix成立以来直到1999年，他担任外科产品副总裁。他还担任过一些卫生保健公司的董事会成员。1984年他以优等成绩获得了the Hebrew University of Jerusalem 的生物学学士学位，Hebrew University of Jerusalem的生物学博士学位和欧洲工商管理学院（ INSEAD，枫丹白露）的工商管理硕士学位。
Oded S. Lieberman has served as our Chief Executive Officer since December 2007 and as the Chairman of our board of directors from 2005 to 2013. From 2000 to 2004 Dr. Lieberman served as Chief Executive Officer and President of Proteologics, Inc. Dr. Lieberman served as Vice President of Surgical Products with Omrix Biopharmaceuticals, Ltd., or Omrix, since its founding in 1995 until 1999. Dr. Lieberman has also served as a member of the boards of several health care companies. Dr. Lieberman received a BSc in Biology cum laude in 1984 from the Hebrew University of Jerusalem and holds both a PhD in Biology from the Hebrew University of Jerusalem and an MBA from INSEAD (Fontainebleau).- Oded S. Lieberman，2007年12月以来，他一直是我们的首席执行官。从2005年到2013年，他担任我们董事会的主席。从2000年到2004年，他担任Proteologics, Inc.的首席执行官和总裁。1995年Omrix Biopharmaceuticals, Ltd.或Omrix成立以来直到1999年，他担任外科产品副总裁。他还担任过一些卫生保健公司的董事会成员。1984年他以优等成绩获得了the Hebrew University of Jerusalem 的生物学学士学位，Hebrew University of Jerusalem的生物学博士学位和欧洲工商管理学院（ INSEAD，枫丹白露）的工商管理硕士学位。
- Oded S. Lieberman has served as our Chief Executive Officer since December 2007 and as the Chairman of our board of directors from 2005 to 2013. From 2000 to 2004 Dr. Lieberman served as Chief Executive Officer and President of Proteologics, Inc. Dr. Lieberman served as Vice President of Surgical Products with Omrix Biopharmaceuticals, Ltd., or Omrix, since its founding in 1995 until 1999. Dr. Lieberman has also served as a member of the boards of several health care companies. Dr. Lieberman received a BSc in Biology cum laude in 1984 from the Hebrew University of Jerusalem and holds both a PhD in Biology from the Hebrew University of Jerusalem and an MBA from INSEAD (Fontainebleau).
- Sheila Oren
Sheila Oren，2008年9月以来，他担任我们临床和管理事务副总裁。从2003年到2008年，他担任Teva的医学董事，负责的两个创新药物临床开发和营销。他目前担任New Generation Technology NGT（技术孵化器）投资委员会和顾问委员会的成员和MedWell Laboratories Ltd.的董事。他持有Sackler School of Medicine, Tel Aviv University的硕士学位和the Interdisciplinary Center, Herzliya的工商管理硕士学位。
Sheila Oren has served as our Chief Medical Officer since October 2016. Prior to that, she had served as our Vice President of Clinical and Regulatory Affairs since September 2008. From 2003 to 2008 Dr. Oren served as Medical Director at Teva and was responsible for the clinical development and marketing of two innovative drugs. Dr. Oren currently serves as a member of the investment committee and advisory board of New Generation Technology NGT, a technology incubator, and as a director of MedWell Laboratories Ltd. Dr. Oren holds an MD from the Sackler School of Medicine, Tel Aviv University and an MBA from the Interdisciplinary Center, Herzliya.- Sheila Oren，2008年9月以来，他担任我们临床和管理事务副总裁。从2003年到2008年，他担任Teva的医学董事，负责的两个创新药物临床开发和营销。他目前担任New Generation Technology NGT（技术孵化器）投资委员会和顾问委员会的成员和MedWell Laboratories Ltd.的董事。他持有Sackler School of Medicine, Tel Aviv University的硕士学位和the Interdisciplinary Center, Herzliya的工商管理硕士学位。
- Sheila Oren has served as our Chief Medical Officer since October 2016. Prior to that, she had served as our Vice President of Clinical and Regulatory Affairs since September 2008. From 2003 to 2008 Dr. Oren served as Medical Director at Teva and was responsible for the clinical development and marketing of two innovative drugs. Dr. Oren currently serves as a member of the investment committee and advisory board of New Generation Technology NGT, a technology incubator, and as a director of MedWell Laboratories Ltd. Dr. Oren holds an MD from the Sackler School of Medicine, Tel Aviv University and an MBA from the Interdisciplinary Center, Herzliya.
- Oron Yacoby Zeevi
Oron Yacoby Zeevi自2016年10月起担任首席科学官。此前，她曾担任我们的研究与开发Vice President（2010年10月以来）。从2008年2月到2010年10月，Yacoby-Zeevi博士担任我们的研究Vice President。从2004年7月到2008年1月，她曾担任Harlan Biotech Israel Ltd.的首席科学官，在那里她曾设计和领导多种小分子药物和生物制剂的研究与开发计划和符合GLP的临床前开发，涉及多种适应症，包括中枢神经系统疾病。2004年之前，Yacoby-Zeevi博士担任Insight Biopharmaceuticals Ltd.的研发组组长。Yacoby-Zeevi博士是超过15项专利的发明者。她持有耶路撒冷希伯来大学（the Hebrew University of Jerusalem）的Koret兽医学院的兽医博士学位，以及the Ben-Gurion University of Be’er Sheva的微生物学和免疫学博士学位。
Oron Yacoby Zeevi has served as Chief Scientific Officer since October 2016. Prior to that, she had served as our Vice President of Research and Development since October 2010. From February 2008 to October 2010 Dr. Yacoby-Zeevi served as our Vice President of Research. From July 2004 to January 2008 Dr. Yacoby-Zeevi served as Chief Science Officer at Harlan Biotech Israel Ltd. where she designed and led research and development programs and GLP-compliant preclinical development of numerous small molecule drugs and biologics in various indications, including CNS diseases. Prior to 2004 Dr. Yacoby-Zeevi served as R&D team leader at Insight Biopharmaceuticals Ltd. Dr. Yacoby-Zeevi is the inventor of over 15 patents. She holds a Doctor of Veterinary Medicine degree from the Koret School of Veterinary Medicine of the Hebrew University of Jerusalem and a PhD in microbiology and immunology from the Ben-Gurion University of Be'er Sheva.- Oron Yacoby Zeevi自2016年10月起担任首席科学官。此前，她曾担任我们的研究与开发Vice President（2010年10月以来）。从2008年2月到2010年10月，Yacoby-Zeevi博士担任我们的研究Vice President。从2004年7月到2008年1月，她曾担任Harlan Biotech Israel Ltd.的首席科学官，在那里她曾设计和领导多种小分子药物和生物制剂的研究与开发计划和符合GLP的临床前开发，涉及多种适应症，包括中枢神经系统疾病。2004年之前，Yacoby-Zeevi博士担任Insight Biopharmaceuticals Ltd.的研发组组长。Yacoby-Zeevi博士是超过15项专利的发明者。她持有耶路撒冷希伯来大学（the Hebrew University of Jerusalem）的Koret兽医学院的兽医博士学位，以及the Ben-Gurion University of Be’er Sheva的微生物学和免疫学博士学位。
- Oron Yacoby Zeevi has served as Chief Scientific Officer since October 2016. Prior to that, she had served as our Vice President of Research and Development since October 2010. From February 2008 to October 2010 Dr. Yacoby-Zeevi served as our Vice President of Research. From July 2004 to January 2008 Dr. Yacoby-Zeevi served as Chief Science Officer at Harlan Biotech Israel Ltd. where she designed and led research and development programs and GLP-compliant preclinical development of numerous small molecule drugs and biologics in various indications, including CNS diseases. Prior to 2004 Dr. Yacoby-Zeevi served as R&D team leader at Insight Biopharmaceuticals Ltd. Dr. Yacoby-Zeevi is the inventor of over 15 patents. She holds a Doctor of Veterinary Medicine degree from the Koret School of Veterinary Medicine of the Hebrew University of Jerusalem and a PhD in microbiology and immunology from the Ben-Gurion University of Be'er Sheva.
- Roy Golan
Roy Golan，自2025年3月起担任My Size, Inc.旗下公司Size，Inc.旗下公司Size，Inc.董事会成员。他自2024年7月起担任财务顾问，目前还自2025年3月起担任LiveKidney.Bio的首席财务官，并自2024年7月起担任纳斯达克上市公司NeuroSense Therapeutics Ltd.（NASDAQ：NRSN）的董事，该公司开发严重神经退行性疾病的治疗方法。Golan先生此前曾担任Ayala Pharmaceuticals, Inc.（OTCQX：ADXS）的首席财务官，该公司是一家临床阶段的肿瘤学公司，该公司于2023年10月与BioSight Ltd.合并，后者是一家开发血液恶性肿瘤和疾病创新疗法的私营制药公司，直至2024年6月。2019年至2023年，Golan先生担任BioSight Ltd.的执行副总裁兼首席财务官。2018年至2019年，Golan先生担任Exalenz Bioscience Ltd.（TASE：EXEN）的总裁兼首席财务官，该公司是一家特拉维夫证券交易所上市的全球性商业阶段诊断公司，开发了其BreathID技术平台，通过在胃肠病学和肝病学领域提供基于呼吸的测试来改善患者护理，后被Meridian Bioscience, Inc.（纳斯达克股票代码：VIVO）收购。从2015年到2018年，Golan先生通过首次公开募股在NeuroDerm（NASDAQ：NDRM）担任首席财务官，该公司是一家在纳斯达克上市的临床阶段制药公司，开发针对中枢神经系统疾病的下一代药物-设备组合，直至被Mitsubishi Tanabe Pharma Group Company收购，在此之前他曾担任其财务副总裁。Golan先生拥有Bar Ilan大学的法学硕士学位以及Rishon LeZion管理学院的学士学位，同时也是一名持牌注册会计师。
Roy Golan,has served as a member of My Size, Inc.'s Size, Inc.'s Size, Inc.'s Size, Inc. board of directors since March 2025. He acts as a financial advisor since July 2024 and also currently serves as Chief Financial Officer of LiveKidney.Bio since March 2025 and as a director of Neurosense Therapeutics Ltd. (NASDAQ: NRSN), a Nasdaq listed company developing treatments for severe neurodegenerative diseases, since July 2024. Mr. Golan previously served as the Chief Financial Officer of Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, from its merger with BioSight Ltd., a private pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, in October 2023 until June 2024. From 2019 to 2023, Mr. Golan served as Executive VP and Chief Financial Officer of BioSight Ltd. From 2018 to 2019, Mr. Golan served as President and Chief Financial Officer of Exalenz Bioscience Ltd. (TASE: EXEN), a Tel Aviv Stock Exchange listed global, commercial-stage diagnostics company which developed its BreathID technology platform to improve patient care by providing breath-based tests in the fields of gastroenterology and hepatology and was later acquired by Meridian Bioscience, Inc. (NASDAQ: VIVO). From 2015 to 2018, Mr. Golan served as the Chief Financial Officer of NeuroDerm (NASDAQ: NDRM), a Nasdaq listed clinical-stage pharmaceutical company developing next-generation drug-device combinations for central nervous system disorders, through its initial public offering until its acquisition by Mitsubishi Tanabe Pharma Group Company, and prior thereto he served as their VP Finance. Mr. Golan holds an LLM from Bar Ilan University as well as a BA from The College of Management in Rishon LeZion and is also a licensed CPA.- Roy Golan，自2025年3月起担任My Size, Inc.旗下公司Size，Inc.旗下公司Size，Inc.董事会成员。他自2024年7月起担任财务顾问，目前还自2025年3月起担任LiveKidney.Bio的首席财务官，并自2024年7月起担任纳斯达克上市公司NeuroSense Therapeutics Ltd.（NASDAQ：NRSN）的董事，该公司开发严重神经退行性疾病的治疗方法。Golan先生此前曾担任Ayala Pharmaceuticals, Inc.（OTCQX：ADXS）的首席财务官，该公司是一家临床阶段的肿瘤学公司，该公司于2023年10月与BioSight Ltd.合并，后者是一家开发血液恶性肿瘤和疾病创新疗法的私营制药公司，直至2024年6月。2019年至2023年，Golan先生担任BioSight Ltd.的执行副总裁兼首席财务官。2018年至2019年，Golan先生担任Exalenz Bioscience Ltd.（TASE：EXEN）的总裁兼首席财务官，该公司是一家特拉维夫证券交易所上市的全球性商业阶段诊断公司，开发了其BreathID技术平台，通过在胃肠病学和肝病学领域提供基于呼吸的测试来改善患者护理，后被Meridian Bioscience, Inc.（纳斯达克股票代码：VIVO）收购。从2015年到2018年，Golan先生通过首次公开募股在NeuroDerm（NASDAQ：NDRM）担任首席财务官，该公司是一家在纳斯达克上市的临床阶段制药公司，开发针对中枢神经系统疾病的下一代药物-设备组合，直至被Mitsubishi Tanabe Pharma Group Company收购，在此之前他曾担任其财务副总裁。Golan先生拥有Bar Ilan大学的法学硕士学位以及Rishon LeZion管理学院的学士学位，同时也是一名持牌注册会计师。
- Roy Golan,has served as a member of My Size, Inc.'s Size, Inc.'s Size, Inc.'s Size, Inc. board of directors since March 2025. He acts as a financial advisor since July 2024 and also currently serves as Chief Financial Officer of LiveKidney.Bio since March 2025 and as a director of Neurosense Therapeutics Ltd. (NASDAQ: NRSN), a Nasdaq listed company developing treatments for severe neurodegenerative diseases, since July 2024. Mr. Golan previously served as the Chief Financial Officer of Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, from its merger with BioSight Ltd., a private pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, in October 2023 until June 2024. From 2019 to 2023, Mr. Golan served as Executive VP and Chief Financial Officer of BioSight Ltd. From 2018 to 2019, Mr. Golan served as President and Chief Financial Officer of Exalenz Bioscience Ltd. (TASE: EXEN), a Tel Aviv Stock Exchange listed global, commercial-stage diagnostics company which developed its BreathID technology platform to improve patient care by providing breath-based tests in the fields of gastroenterology and hepatology and was later acquired by Meridian Bioscience, Inc. (NASDAQ: VIVO). From 2015 to 2018, Mr. Golan served as the Chief Financial Officer of NeuroDerm (NASDAQ: NDRM), a Nasdaq listed clinical-stage pharmaceutical company developing next-generation drug-device combinations for central nervous system disorders, through its initial public offering until its acquisition by Mitsubishi Tanabe Pharma Group Company, and prior thereto he served as their VP Finance. Mr. Golan holds an LLM from Bar Ilan University as well as a BA from The College of Management in Rishon LeZion and is also a licensed CPA.
- Sharon Cohen Vered
Sharon Cohen Vered，2008年8月以来，她担任我们化学、制造和控制负责人。从1993年到2008年，她担任Teva Pharmaceuticals Ltd.的各种职位，最后，她担任无菌剂型发展负责人。她持有 the Technion - Israel Institute of Technology化学工程学士学位和生物医学工程硕士学位和Tel Aviv University的生物化学博士学位。
Sharon Cohen Vered has served as our Vice President, Chemistry, Manufacturing and Controls since August 2008. From 1993 to 2008 Dr. Cohen-Vered was employed at Teva Pharmaceuticals Ltd., where she served in various positions; most recently, she was the Head of Sterile Dosage Form Development. Dr. Cohen-Vered holds a BSc in chemical engineering and an MSc in biomedical engineering from the Technion - Israel Institute of Technology and a PhD in biochemistry from Tel Aviv University.- Sharon Cohen Vered，2008年8月以来，她担任我们化学、制造和控制负责人。从1993年到2008年，她担任Teva Pharmaceuticals Ltd.的各种职位，最后，她担任无菌剂型发展负责人。她持有 the Technion - Israel Institute of Technology化学工程学士学位和生物医学工程硕士学位和Tel Aviv University的生物化学博士学位。
- Sharon Cohen Vered has served as our Vice President, Chemistry, Manufacturing and Controls since August 2008. From 1993 to 2008 Dr. Cohen-Vered was employed at Teva Pharmaceuticals Ltd., where she served in various positions; most recently, she was the Head of Sterile Dosage Form Development. Dr. Cohen-Vered holds a BSc in chemical engineering and an MSc in biomedical engineering from the Technion - Israel Institute of Technology and a PhD in biochemistry from Tel Aviv University.
- Revital Mandil Levin
Revital Mandil Levin，2014年1月以来，他担任我们商业发展负责人。在加入我们之前从2004年10月到2013年12月，他担任HealOr Ltd.（临床阶段专业生物制药公司）业务发展副总裁。2004年之前，他担任Proteologics Ltd的业务发展经理。他获得博士巴伊兰大学（Bar-Ilan University）生物化学博士学位 Israeli College of Management - Technology Company Management Program的工商管理硕士学位。
Revital Mandil Levin has served as our Vice President, Corporate Development since October 2016. Prior to that, she had served as Head of Business Development since January 2014. Prior to joining us, from October 2004 to December 2013 Dr. Mandil-Levin served as the Vice President of Business Development at HealOr Ltd., a clinical-stage specialty biopharmaceutical company. Prior to 2004 Dr. Mandil-Levin served as the Business Development Manager at Proteologics Ltd. Dr. Mandil-Levin holds a PhD in biochemistry from Bar-Ilan University and an MBA from the Israeli College of Management - Technology Company Management Program.- Revital Mandil Levin，2014年1月以来，他担任我们商业发展负责人。在加入我们之前从2004年10月到2013年12月，他担任HealOr Ltd.（临床阶段专业生物制药公司）业务发展副总裁。2004年之前，他担任Proteologics Ltd的业务发展经理。他获得博士巴伊兰大学（Bar-Ilan University）生物化学博士学位 Israeli College of Management - Technology Company Management Program的工商管理硕士学位。
- Revital Mandil Levin has served as our Vice President, Corporate Development since October 2016. Prior to that, she had served as Head of Business Development since January 2014. Prior to joining us, from October 2004 to December 2013 Dr. Mandil-Levin served as the Vice President of Business Development at HealOr Ltd., a clinical-stage specialty biopharmaceutical company. Prior to 2004 Dr. Mandil-Levin served as the Business Development Manager at Proteologics Ltd. Dr. Mandil-Levin holds a PhD in biochemistry from Bar-Ilan University and an MBA from the Israeli College of Management - Technology Company Management Program.
- Eran Shor
Eran Shor，他于2016年2月加入我们公司，担任我们的设备副总裁。加入我们公司之前，他曾任职PerfAction Technologies公司，在那里他曾领导医学审美的药物输送装置的开发，担任首席运营官（从2009年9月到2013年6月）、首席执行官（从2013年7月到2016年2月）。此前，他曾担任GI View公司（医疗设备初创企业，开发自行筛选结肠镜检查解决方案）的多种职务，最近担任研发副总裁（从2003年到2009年9月）。他持有特拉维夫大学（Tel Aviv University）的机械工程学士学位。
Eran Shor joined our company in February 2016 as our Vice President, Devices. Prior to joining our company, Mr. Shor was with PerfAction Technologies, where he led the development of a drug delivery device for the medical esthetic field as the COO from September 2009 to June 2013 and then CEO (from July 2013 until February 2016). Before that, he served in several positions (most recently, as VP, R&D) at GI View, a medical device start-up that develops a self-propelled screening colonoscopy solution, from 2003 until September 2009. Mr. Shor holds a B.Sc. in Mechanical Engineering from Tel Aviv University.- Eran Shor，他于2016年2月加入我们公司，担任我们的设备副总裁。加入我们公司之前，他曾任职PerfAction Technologies公司，在那里他曾领导医学审美的药物输送装置的开发，担任首席运营官（从2009年9月到2013年6月）、首席执行官（从2013年7月到2016年2月）。此前，他曾担任GI View公司（医疗设备初创企业，开发自行筛选结肠镜检查解决方案）的多种职务，最近担任研发副总裁（从2003年到2009年9月）。他持有特拉维夫大学（Tel Aviv University）的机械工程学士学位。
- Eran Shor joined our company in February 2016 as our Vice President, Devices. Prior to joining our company, Mr. Shor was with PerfAction Technologies, where he led the development of a drug delivery device for the medical esthetic field as the COO from September 2009 to June 2013 and then CEO (from July 2013 until February 2016). Before that, he served in several positions (most recently, as VP, R&D) at GI View, a medical device start-up that develops a self-propelled screening colonoscopy solution, from 2003 until September 2009. Mr. Shor holds a B.Sc. in Mechanical Engineering from Tel Aviv University.
- Tami Yardeni
Tami Yardeni自2016年7月起担任我们的首席运营官。在加入我们公司之前，Yardeni女士在Teva Pharmaceutical Industries或Teva任职17年，最近担任副总裁，全球临床运营主管，她曾负责全球研发计划的运营执行，涉及从第一阶段到监管批准和商业化的所有迹象。从1999年到2011年，她曾担任Teva公司的负责生物识别领域的职务，包括管理全球卓越数据管理中心6年，在那里她曾领导数据管理外包和离岸的战略规划和执行。以及各种生物识别功能的收购后集成过程。她在海法大学获得统计学学士学位和应用统计学硕士学位。
Tami Yardeni has served as our Chief Operating Officer since July 2016. Prior to joining our company, Ms. Yardeni served for 17 years at Teva Pharmaceutical Industries, or Teva, most recently as VP, Head of Global Clinical Operation, Global R&D where she was responsible for the operational execution of global development programs across all indications from Phase I to regulatory approval and commercialization. From 1999 to 2011 Ms. Yardeni held positions of increasing responsibility in the area of Biometrics at Teva, including six years of managing the Global Data Management Center of Excellence, where she led the strategic planning and execution of data management outsourcing and off-shoring, as well as the post-acquisition integration processes for various biometrics functions. She received both her B.A. in Statistics and M.A. in Applied Statistics from Haifa University.- Tami Yardeni自2016年7月起担任我们的首席运营官。在加入我们公司之前，Yardeni女士在Teva Pharmaceutical Industries或Teva任职17年，最近担任副总裁，全球临床运营主管，她曾负责全球研发计划的运营执行，涉及从第一阶段到监管批准和商业化的所有迹象。从1999年到2011年，她曾担任Teva公司的负责生物识别领域的职务，包括管理全球卓越数据管理中心6年，在那里她曾领导数据管理外包和离岸的战略规划和执行。以及各种生物识别功能的收购后集成过程。她在海法大学获得统计学学士学位和应用统计学硕士学位。
- Tami Yardeni has served as our Chief Operating Officer since July 2016. Prior to joining our company, Ms. Yardeni served for 17 years at Teva Pharmaceutical Industries, or Teva, most recently as VP, Head of Global Clinical Operation, Global R&D where she was responsible for the operational execution of global development programs across all indications from Phase I to regulatory approval and commercialization. From 1999 to 2011 Ms. Yardeni held positions of increasing responsibility in the area of Biometrics at Teva, including six years of managing the Global Data Management Center of Excellence, where she led the strategic planning and execution of data management outsourcing and off-shoring, as well as the post-acquisition integration processes for various biometrics functions. She received both her B.A. in Statistics and M.A. in Applied Statistics from Haifa University.
- Ziva Mesika
Ziva Mesika自2016年10月起担任监管事务Vice President RA。加入我们之前，她曾担任Teva Pharmaceuticals Ltd.的增长市场专业（创新）RA和全球RA生物仿制药项目主管，在那里她曾任职6年。2010年之前，她曾在多家公司担任RA、QA和研发方面的多个管理职位，包括SciGen Transpharma Ltd.、CompugenLtd.和InterPharm Ltd.。Mesia女士拥有学士学位。耶路撒冷希伯来大学生物学学士学位。
Ziva Mesika has served as our Vice President of Regulatory Affairs RA since October 2016. Prior to joining us, Ms. Mesika served as Head of Growth Markets Specialty (Innovative) RA and Global RA Biosimilars Projects at Teva Pharmaceuticals Ltd., where she worked for six years. Prior to 2010 she had multiple managerial positions in RA, QA and R&D in several companies, including SciGen Transpharma Ltd., Compugen Ltd., and Interpharm Ltd. Ms. Mesia holds a B.Sc. in Biology from Hebrew University, Jerusalem.- Ziva Mesika自2016年10月起担任监管事务Vice President RA。加入我们之前，她曾担任Teva Pharmaceuticals Ltd.的增长市场专业（创新）RA和全球RA生物仿制药项目主管，在那里她曾任职6年。2010年之前，她曾在多家公司担任RA、QA和研发方面的多个管理职位，包括SciGen Transpharma Ltd.、CompugenLtd.和InterPharm Ltd.。Mesia女士拥有学士学位。耶路撒冷希伯来大学生物学学士学位。
- Ziva Mesika has served as our Vice President of Regulatory Affairs RA since October 2016. Prior to joining us, Ms. Mesika served as Head of Growth Markets Specialty (Innovative) RA and Global RA Biosimilars Projects at Teva Pharmaceuticals Ltd., where she worked for six years. Prior to 2010 she had multiple managerial positions in RA, QA and R&D in several companies, including SciGen Transpharma Ltd., Compugen Ltd., and Interpharm Ltd. Ms. Mesia holds a B.Sc. in Biology from Hebrew University, Jerusalem.